Seema Ali Bhat MD

Physician

460 W 10th AveColumbus, OH 43210
Phone+1 614-293-3196
Fax+1 614-293-4812

Dr. Bhat is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Bhat's full profile Already have an account?

Summary

Dr. Seema A. Bhat is an Oncologist in Columbus, OH and is affiliated with multiple hospitals in the area, including James Cancer Hospital and Solove Research Institute and Ohio State University Wexner Medical Center. She received her medical degree from Government Medical College of Jammu and Kashmir and has been in practice for 19 years. She also speaks multiple languages, including Kashmiri, Urdu and Hindi. She specializes in hematologic/Medical oncology and is experienced in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, cold agglutinin disease, Autoimmune hemolytic anemia, Lymphomas and related disorders.

Education & Training

University at BuffaloFellowship, Hematology and Medical Oncology, 2008 - 2011
University at BuffaloResidency, Internal Medicine, 2004 - 2008
Government Medical College of Jammu and KashmireClass of 1999

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

OH State Medical License 2018 - 2027
NY State Medical License 2011 - 2020
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification Sunrise Patient Portal and Sunrise Ambulatory Care EHR, Allscripts, 2013-2014
CMS Meaningful Use Stage 1 Certification Sunrise Patient Portal and Sunrise Acute Care EHR, Allscripts, 2013-2014
CMS Meaningful Use Stage 1 Certification Sunrise Acute Care Module Set, Allscripts, 2013-2014

Clinical Trials

Ofatumumab and Bortezomib in Treating Patients With Previously Untreated Waldenstrom Macroglobulinemia
TERMINATED
PHASE2
First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas Start of enrollment: 2020 Mar 13
TERMINATED
PHASE1, PHASE2

Publications & Presentations

PubMed

Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocy...
Matthew S Davids, Toby A Eyre, Jennifer A Woyach, Lindsey E Roeker, Alessandra Ferrajoli
Lancet. 2026-08-01
Outcomes of patients with chronic lymphocytic leukemia discontinuing covalent Bruton tyrosine kinase inhibitors due to adverse events.
Anthony G Mansour, Ying Huang, J Phillip Pemberton, Aseel Alsouqi, Adam S Kittai
Leukemia. 2026-08-01
Pharmacologic activity, safety, and preliminary efficacy of GEN3009, a CD37-targeting DuoHexaBody, in relapsed or refractory B-cell non-Hodgkin's lymphoma.
Farrukh T Awan, Joshua T Gamse, Marije B Overdijk, Esther C W Breij, Maria Jure-Kunkel
Journal for Immunotherapy of Cancer. 2026-07-07

Abstracts/Posters

Resistance to Acalabrutinib in CLL Is Mediated Primarily By BTK Mutations
Seema A. Bhat, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Final Results of a Phase 2 Trial of Early Intervention Ibrutinib with Vaccinations in Patients with Asymptomatic, High-Risk CLL
Seema A. Bhat, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Ibrutinib Treatment in CLL Patients Improves T Cell Function and Blinatumomab Redirected Cytotoxicity
Seema A. Bhat, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Press Mentions

CLL: Hematologists Face off on Best Long-Term StrategyJuly 9th, 2025
ICML 2025: Progress and Future Directions in CLL TreatmentJuly 7th, 2025
Novel Therapies and Their Impact on Treatment Pathways for Chronic Lymphocytic LeukemiaJanuary 13th, 2025